Pharma BD Deal Intelligence
Novartis and PeptiDream ink potential $2.7B deal to expand radioligand discovery partnership using proprietary macrocyclic peptide platform technology.
PMLiVE reports Novartis and PeptiDream expanded their peptide discovery collaboration in a deal worth over $2.8B total ($180M upfront plus up to $2.71B in…
Novartis paid $180M upfront to expand its collaboration with PeptiDream for macrocyclic peptide platform access.
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Novartis expanded its collaboration with PeptiDream, paying $180M upfront for access to its macrocyclic peptide discovery platform across multiple undisclosed indications.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / PeptiDream Inc. (this deal) | 2024 | $2.9B | 71 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2024 deals · Novartis AG deals · Oncology deals